Eight Cambridge academics are among 48 of the UK’s world leading researchers who have been elected to join the prestigious Fellowship of the Academy of Medical Sciences.
Almost 30 years on from the discovery of the genetic defect that causes cystic fibrosis, treatment options are still limited and growing antibiotic resistance presents a grave threat. Now, a team of researchers from across Cambridge, in a major new centre supported by the Cystic Fibrosis Trust, hopes to turn fortunes around.
Read more about the female scientists at Cambridge taking their fields by storm - and using International Women's Day to encourage others to do the same.
Leprosy hijacks our immune system, turning an important repair mechanism into one that causes potentially irreparable damage to our nerve cells, according to new research that uses zebrafish to study the disease. As such, the disease may share common characteristics with conditions such as multiple sclerosis.
Gene editing using ‘molecular scissors’ that snip out and replace faulty DNA could provide an almost unimaginable future for some patients: a complete cure. Cambridge researchers are working towards making the technology cheap and safe, as well as examining the ethical and legal issues surrounding one of the most exciting medical advances of recent times.
An open source, 3D-printable microscope that forms the cornerstone of rapid, automated water testing kits for use in low and middle-income countries, has helped a Cambridge researcher and his not-for-profit spin-out company win the top prize in this year’s Vice-Chancellor’s Impact Awards at the University of Cambridge.
Trevor Lawley and Gordon Dougan are bug hunters, albeit not the conventional kind. The bugs they collect are invisible to the naked eye. And even though we’re teeming with them, researchers are only beginning to discover how they keep us healthy – and how we could use these bugs as drugs.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.